For instance, Mangadlao et al. (2018) demonstrated the successful targeting of prostate cancer cells using anti-PSMA (prostate-specific membrane antigen) antibody-conjugated gold NPs. This evidence concerns the gene FOLH1 and prostate carcinoma.